非小细胞肺癌组织中CD133表达及临床意义的Meta分析  

Meta analysis on CD133 expression and clinical significance in non-small cell lung cancer

作　　者：苟云久[1] 何晓东[2] 谢定雄 杨克虎[4] 刘雅莉[4] 张建华[1] 

机构地区：[1]兰州大学第二医院,甘肃省兰州市730000 [2]兰州大学,甘肃省兰州市730000 [3]兰州市第一人民医院,甘肃省兰州市730000 [4]兰州大学循证医学中心,甘肃省兰州市730000

出　　处：《中国组织工程研究》2013年第23期4292-4298,共7页Chinese Journal of Tissue Engineering Research

基　　金：兰州大学中央高校基本科研业务费专项资金(lzujbky-2012-171)~~

摘　　要：背景:肿瘤干细胞标志物CD133在非小细胞肺癌发生、发展过程中的作用存在争议。目的:系统评价有关非小细胞肺癌组织中CD133表达及临床意义的病例对照研究。方法:计算机检索PubMed、EMBASE、Web of Science、中国生物医学文献数据库(CBM)、中文科技期刊全文数据库(VIP)、中国期刊全文数据库(CNKI)及万方数据库,并辅以文献追溯的方法,收集国内外发表的相关病例对照研究,检索时间均从建库至2012年9月。两位研究者按纳入排除标准筛选文献并评价纳入研究质量,应用RevMan5.1软件进行Meta分析。结果与结论:共纳入10个病例对照研究,包含非小细胞肺癌组织808例。Meta分析结果显示:在CD133表达方面,非小细胞肺癌组织比癌旁组织或正常组织高[OR=8.15,95%CI(4.61,14.41),P<0.00001],有淋巴结转移的非小细胞肺癌组织比无淋巴结转移的高[OR=1.83,95%CI(1.06,3.17),P=0.03],中低分化的非小细胞肺癌组织比高分化的高[OR=2.09,95%CI(1.42,3.08),P=0.0002];非小细胞肺癌组织病理分级Ⅰ级和临床Ⅱ-Ⅲ级CD133表达的差异无显著性意义[OR=1.06,95%CI(0.66,1.70),P=0.81]。现有研究表明,CD133在非小细胞肺癌发生、发展过程中可能起重要作用,但其能否作为非小细胞肺癌诊断及预后的可靠指标尚不确定,需要进行更多设计严谨、细致的高质量流行病学研究来进一步证实。BACKGROUND： Argument exists about the role of tumor stem cell marker CD133 in the development of non-small cell lung cancer. OBJECTIVE： To systemically evaluate the case-control studies addressing the CD133 expression and clinical significance in non-small cell lung cancer. METHODS： A computer-based retrieval of PubMed Wanfang Database was performed from their estab EMBASE, Web of Science, CBM, VIP, CNKI and shment to September 2012 for case-control studies investigating the CD133 expression and clinical significance in non-small cell lung cancer. After evaluating methodological quality of studies met the inclusion criteria, we analyzed the data with meta analysis using RevMan 5.1 software. RESULTS AND CONCLUSION： Ten case-control studies were identified, involving 808 cases with non-small cell lung cancer. Meta analysis results showed that, the positive rate of CD133 expression in non-small cell lung cancer was significantly higher than that in normal lung tissues [odd ratio （OR）=8.15, 95% confidence interval （CO （4.61, 14.41）, P 〈 0.000 01], and also higher in non-small cell lung cancer tissue with lymph node metastasis than that with non-lymph node metastasis [OR = 1.83, 95%CI （1.06, 3.17）, P = 0.03], as well as higher in non-small cell lung cancer tissue with low and moderate differentiation than that with high differentiation [OR=2.09, 95%C1（1.42, 3.08）, P=-0.000 2]. There was no significant difference in the CD133 expression between pathologic grading Ⅰ vs. pathologic grading Ⅱ-Ⅲ non-small cell lung cancer tissue [OR = 1.06, 95%CI （0.66, 1.70）, P=0.81]. Experimental findings indicate that, CD133 plays a crucial role in the development of non-small call lung cancer. However, it is still unclear whether CD133 could be regarded a marker to diagnose and predict non-small cell lung cancer, which needs more high-quality case-control studies to explore the question clearly.

关 键 词：干细胞 干细胞循证医学 CD133 肿瘤干细胞 非小细胞肺癌 肺癌 META分析 病例对照研究 淋巴结转移 细胞分化 病理分期 其他基金 

分 类 号：R394.2[医药卫生—医学遗传学]